Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 5,059 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Advanced Solid Tumors With MAPK Pathway Mutations
Interventions: D3S-002, D3S-001; Drug
Lead sponsor: D3 Bio (Wuxi) Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Detroit, Michigan • New York, New York • Nashville, Tennessee + 1 more

Conditions: Neoplasm
Interventions: preladenant, pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Major Depressive Disorder
Interventions: Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Coronavirus Disease (COVID-19)
Interventions: Molnupiravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,735 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 32
States / cities: Peoria, Arizona • Los Angeles, California • North Hollywood, California + 27 more

Conditions: Non Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions: lenvatinib, everolimus; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Tampa, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more

Conditions: HIV Infections
Interventions: Saquinavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Sherman Oaks, California + 6 more

Conditions: Parkinson Disease
Interventions: Placebo, inosine; Drug
Lead sponsor: The Parkinson Study Group; Network
Eligibility: 30 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 16
States / cities: Los Angeles, California • Manchester, Connecticut • New Haven, Connecticut + 12 more

Conditions: Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Interventions: Afimetoran, Placebo; Drug
Lead sponsor: Beeline Medicines Corporation; Industry
Eligibility: 16 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: San Diego, California • DeBary, Florida • Missoula, Montana

Conditions: Chronic Lymphocytic Leukemia
Interventions: Ublituximab, Umbralisib, Ibrutinib, Venetoclax, Acalabrutinib Oral Capsule; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Boston, Massachusetts • Hackensack, New Jersey • New York, New York

Conditions: Olfactory Disorder, Anosmia, Viral Infection, Theophylline Causing Adverse Effects in Therapeutic Use, Smell Disorder
Interventions: Theophylline, Saline Nasal; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bariatric Surgery, Cardiac Surgery With Sternotomy, Post-operative Pain
Interventions: Suzetrigine, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 85 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: ADHD
Interventions: Placebo, AZD3480; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Knee Osteoarthritis
Interventions: Synvisc-One Injection, Sham Injection; Device · Other
Lead sponsor: Elaine Husni; Other
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Parkinson's Disease
Interventions: CD-LD IR, IPX203 180 mg, IPX203 270 mg, Rytary 195 mg, Rytary 145 mg; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 11
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 8 more

Conditions: Center-involved Diabetic Macular Edema (CI-DME)
Interventions: Diabetes Visual Function Study (DiVFuSS) softgels, canola oil placebo softgels, 2 per day; Dietary Supplement · Other
Lead sponsor: ZeaVision, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Olympia, Washington • Tacoma, Washington

Conditions: Eye Strain, Eye Fatigue
Interventions: Blackcurrant, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 30 Years to 60 Years · Female only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Fragile X Syndrome, FXS, Fra(X) Syndrome
Interventions: BPN14770, Placebo; Drug
Lead sponsor: Tetra Discovery Partners; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Thrombosis
Interventions: Vitamin K, 20mg; Dietary Supplement
Lead sponsor: Stephan Moll, MD; Other
Eligibility: 20 Years to 85 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Melanoma
Interventions: Pembrolizumab, Quavonlimab, Vibostolimab, Lenvatinib, ATRA; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 13
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 9 more

Conditions: Post Operative Dental Pain
Interventions: acetaminophen Tablet, acetaminophen Caplet, ibuprofen Liquid-filled capsule, Placebo Tablet, Placebo Caplet, Placebo Liquid-filled capsule; Drug
Lead sponsor: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division; Industry
Eligibility: 17 Years to 50 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Female Sexual Health
Interventions: KSM-66 Ashwagandha® capsule, Identical Placebo capsule; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: dimethyl fumarate, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 19 Years to 58 Years
Enrollment: 1,736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 50
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more

Conditions: ALK-positive Non-small Cell Lung Cancer
Interventions: Ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 7
States / cities: Los Angeles, California • Stanford, California • South Bend, Indiana + 4 more

Conditions: Healthy Volunteers
Interventions: TAK-906; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Search by objective public record fields.

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

Safety of Urate Elevation in Parkinson's Disease

Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Smell Changes & Efficacy of Nasal Theophylline

Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery

An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)

Optimization of Synvisc-One for Knee OA

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema

The Effects of Blackcurrant Supplementation on Eye Health

A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome

Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Study of Acetaminophen (ACM) in Post-operative Dental Pain

Effect of Single Dose of Ashwagandha Root Extract on Sexual Health in Women.

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

Bioavailability and Food Effect Study of Two Formulations of TAK-906